LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial CI
Tourmaline Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. CI
Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. CI
Certain Common Stock of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. CI
Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected MT
US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady MT
Top Premarket Decliners MT
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027 MT
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024 CI
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing MT
Tourmaline Bio Prices $150 Million Common Stock Offering MT
Tourmaline Bio, Inc.(NasdaqGS:TRML) added to NASDAQ Biotechnology Index CI
Tourmaline Bio Joins Nasdaq Biotechnology Index MT
Jefferies Starts Coverage on Tourmaline Bio with Buy Rating, $41 Price Target MT
Tourmaline Bio, Inc. Appoints Clay Siegall to Serve as a Director CI
Tourmaline Bio, Inc. Announces Resignation of Cariad Chester as Member of the Board of Directors CI
Transcript : Tourmaline Bio, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 01:00 PM
Truist Starts Tourmaline Bio With Buy Rating, $43 Price Target MT
North American Morning Briefing : Stock Futures -2- DJ
Talaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Tourmaline Bio, Inc. Presents at Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference, Nov-06-2023 03:50 PM
Tourmaline Bio Insider Bought Shares Worth $280,584, According to a Recent SEC Filing MT
Chart Tourmaline Bio, Inc.
More charts
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is also developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. It is focused on two strategic paths for TOUR006, the first of which it refers to as FcRn+. Its second strategic path is cardiovascular inflammation.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
16.96 USD
Average target price
58.33 USD
Spread / Average Target
+243.95%
Consensus